ArticleImmunology and cell biology2026
CD49a expression defines a metabolically robust, cytokine-biased liver NK cell subset in rhesus macaques during lentivirus infection.
Article in Immunology and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Liver-resident natural killer (LrNK) cells are critical regulators of hepatic immune homeostasis and demonstrate antiviral activity, yet their role in lentivirus infections remains poorly defined. Using a rhesus macaque (RM) model of Simian immunodeficiency virus (SIV) and Simian-human immunodeficiency virus (SHIV) infections, we investigated the phenotypes, metabolic profiles and functional responses of hepatic NK cells across naïve, acutely SIV-infected and chronically SHIV-infected RM. We identified liver-resident (Lr) NK cells as CD3-CD159a/c+CD49a+, whereas CD3-CD159a/c+CD49a- NK cells include circulating NK cell subsets in the liver. Across infection states, CD49a+ LrNK cells exhibited elevated expression of activation markers, including NKG2D, NKp30, NKp46 and CD69, as well as increased expression of metabolic markers, including CD98, Glut1 and MitoTracker. In contrast, Ki-67 expression was reduced in CD49a+ LrNK cells compared with their CD49a- counterparts. Unsupervised clustering revealed that CD49a+ LrNK cells were also marked by high CD69 expression. While total NK cell cytokine secretion was elevated in acute SIV-infected animals, CD49a+ LrNK cells exhibited robust polyfunctional cytokine responses and reduced expression of the cytotoxic marker CD107a upon mitogen stimulation in comparison with CD49a- LrNK cells regardless of infection status. These findings reveal distinct metabolic and functional specialization of hepatic NK cell subsets, underscoring the unique phenotype and functions of CD49a+ LrNK cells in RM, which may offer novel insights and therapeutic opportunities for treating liver inflammation in HIV infection and other chronic liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.